Companies › Cardiff Oncology
1 active drug program in 4 registered trials: 2 Phase 2, 2 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Onvansertib Serine/threonine-protein kinase PLK1 inhibitor | PLK1 | Phase 2 | Metastatic Colorectal Cancer; Small-cell Lung Cancer; Breast Cancer; Pancreatic Cancer | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06106308 | Onvansertib | Phase 2 | Metastatic Colorectal Cancer | Oncology | Nov 2026 |
| NCT05383196 | Onvansertib | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT06736717 | Onvansertib | Phase 1 | Pancreatic Cancer | Oncology | Jan 2027 |
| NCT05450965 | Onvansertib | Phase 2 | Small-cell Lung Cancer | Oncology | Aug 2027 |
Cash and short-term investments of $34m on 2026-06-30; operating cash outflow about $49m a year; runway about 8 months at that burn, to Mar 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Oncolytics Biotech TuHURA Biosciences Actuate Therapeutics Inhibrx Biosciences Genelux
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.